Zulfa Mohammed B Mohammed Omer , MD
Assistant Professor of Clinical
Vontz Center
COM IM Hematology/Oncology Division - 0562
Education
MBBS: University of Khartoum Khartoum, Sudan, 2014
Certifications
American Board of Internal Medicine (Certification Date: 08-31-2020 )
American Board of Internal Medicine (Medical Oncology) (Certification Date: 11-08-2023 )
Clinical Interests
Hematology and Oncology
Bone Marrow Cancers
Specialities
Internal Medicine
Research Support
Grant: #NX-5948-301 Investigators:Byrd, John; Omer, Zulfa 08-24-2023 -09-13-2026 Nurix A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies Role:PI 562050.47 Active Level:Industry
Grant: #M23-324 Investigators:Omer, Zulfa 08-22-2024 -08-22-2027 AbbVie, Inc. A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies Role:PI 791973.77 Hold Level:Industry
Grant: #UCCC-HEM-24-02 Investigators:Omer, Zulfa 02-20-2025 -02-20-2028 Newave Pharmaceuticals, Inc. A Multicenter Parallel 3 Cohort Phase 2 Study of LP-168 and Obinutuzumab for Untreated and Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This. Role:PI 1000000.00 Hold Level:Industry